Formation Bio, an AI and tech-driven drug developer with its pipeline of drug assets, will provide engineering resources, experience operating at the intersection of pharma and AI, ...

Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph ...

Formation Bio has secured $372m in a Series D financing round to bolster its drug pipeline and expedite the expansion of its AI-driven drug development platform. Spearheaded by venture capital ...

Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement.

Formation Bio, a startup focused on applying AI to drug development with backing from OpenAI CEO Sam Altman, has raised over a quarter-billion dollars to support its ambitious product roadmap.

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Formation Bio partners, acquires, or in-licenses drugs from biotech and pharma companies and then it develops those programs using its proprietary technology platform.

Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects. Also Read: Drugmaker Sanofi’s Strong Dupixent ...

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...